Les meilleurs doctors en Israël pour votre Thérapie ciblée - TOP 22 des médecins

Le professeur Ofer Merimsky dirige l'unité d'oncologie des tissus mous et des os au Sourasky Medical Center – le plus grand spécialiste israélien des sarcomes.

• Plus de 30 ans de traitement des sarcomes par thérapies ciblées
• Formation de perfectionnement (Fellowship) en sarcome à l'Institut Gustave Roussy, Paris
• Membre du corps professoral de l'ESMO pour la recherche sur les sarcomes
• Publications approfondies en oncologie orthopédique
• Ancien président de la Société israélienne d'oncologie

Le Dr Pelles Sharon est une oncologue respectée possédant une vaste expérience en thérapie ciblée et autres traitements avancés contre le cancer au centre médical Sourasky.

• Spécialisée dans la thérapie ciblée pour divers cancers
• A contribué à la recherche clinique sur l'attitude des patients oncologiques envers les essais cliniques
• Réalise plusieurs traitements avancés contre le cancer, notamment la thérapie SIRT et l'HIPEC
• Travaille au centre médical Sourasky (Ichilov), un hôpital israélien de premier plan

Le Dr Sarid a publié plus de 30 articles sur la thérapie du cancer et dirige des essais cliniques sur les traitements ciblés au Centre médical Sourasky.

• Spécialisé en chimiothérapie, radiothérapie et thérapie biologique pour divers cancers
• Plus de 15 ans d'expérience en tant qu'oncologue senior au Centre médical Ichilov
• Chargé de cours à l'Université de Tel Aviv – se tient au courant des dernières thérapies
• Membre de l'ESMO et de l'ASCO – suit les directives de traitement internationales

Spécialiste en Gynécologie Oncologique et Radiothérapie au Sourasky Medical Center (Ichilov), axé sur la thérapie ciblée.

• Expérimenté dans les traitements de précision des cancers gynécologiques
• Utilise des techniques de radiothérapie avancées pour un traitement ciblé
• Fait partie d'une équipe d'oncologie de premier plan dans un centre médical de référence

Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.

She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.

Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.

Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).

His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.

He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.

He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Le Dr Ido Wolf dirige le service d'oncologie médicale au Sourasky Medical Center, spécialisé dans la thérapie ciblée.

• Chef du service d'oncologie médicale dans un hôpital israélien de premier plan
• Vaste expérience en oncologie et en médecine interne
• Formation à l'Université Ben Gourion du Néguev
• Son parcours comprend un service au sein des unités médicales de l'armée

Le Dr Raphael dirige l'Initiative nationale de médecine génomique d'Israël et est pionnier dans les essais de thérapies ciblées au centre médical Sourasky.

• Spécialisé dans les tumeurs thoraciques malignes et le profilage génomique complet
• Investigateur principal pour de multiples essais cliniques d'immunothérapie
• Modérateur du Molecular Tumor Board pour l'Israeli Lung Cancer Society
• Récipiendaire de bourses de recherche de l'ESMO et de l'IASLC
• Développe des techniques de biopsie liquide pour le suivi des traitements

Directeur du Service de neuro-oncologie au Sourasky Medical Center – Le Dr Blumental apporte des décennies d'expertise spécialisée dans le domaine de la neuro-oncologie.

• Formation au Memorial Sloan-Kettering Cancer Center
• Neuro-oncologue sénior depuis 1998
• Auparavant, a dirigé le Service de neuro-oncologie au Huntsman Cancer Institute

Directeur de l'hospitalisation en oncologie au Centre médical de Tel Aviv, Ichilov – le Dr Stepfansky dirige des équipes de soins anticancéreux.

• Plus de 20 ans d'expérience en oncologie et en médecine interne
• Chercheur dans plusieurs phases d'essais cliniques en oncologie
• Spécialisé en médecine interne et en oncologie à Ichilov

Le Dr Fredi Aviv apporte 31 ans d'expertise ciblée en oncohématologie au Centre médical Sourasky.

• Se spécialise dans les traitements anticancéreux ciblés pour les troubles sanguins
• Travaille à la Clinique Ichilov – un centre de premier plan pour l'oncologie hématologique
• Vaste expérience des nouvelles approches thérapeutiques

Le Dr Dror Levin est spécialisé dans le traitement des troubles sanguins et du cancer des os chez les enfants au Centre médical Sourasky, l'un des principaux hôpitaux d'Israël.

• Directeur du département d'hématologie et d'oncologie pédiatrique au Centre médical Sourasky
• Coordonne le traitement du cancer des os (sarcome) chez les enfants
• Formé à l'Institut orthopédique Rizzoli en Italie – un leader mondial
• Membre de l'ISPHO (Société israélienne d'hématologie et d'oncologie pédiatrique)

Le Dr Amir est spécialisé en thérapie ciblée avec Keytruda (Pembolizumab) pour le cancer du sein, fort de plus de 30 présentations lors de réunions scientifiques.

• Lauréat du Prix ESMO de Recherche Translationnelle sur le Cancer du Sein en 2013
• Formation par fellowship à l'Institut Jules Bordet et à l'Université Emory
• Membre de la Société Européenne d'Oncologie Médicale (ESMO)
• Ses recherches publiées ont été reconnues deux fois par le Prix ISCORT du Meilleur Article de l'Année

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.